Parkinson's Disease: World Drug Market 2011-2021
NEW YORK, Nov. 2, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Parkinson%s Disease: World Drug Market 2011-2021
http://www.reportlinker.com/p0663861/Parkinson%s-Disease-World-Drug-Market-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
What are the commercial prospects for the treatment of Parkinson's disease? Visiongain's report shows you potential drug revenues to 2021. Find opportunities and forecasts.
Do you want revenue predictions for Parkinson's disease treatments at total world, submarket, product and national levels to 2021? Through our research and analysis we aim to save you time and help in your decisions.
Find out how the drugs Stalevo/Comtess, Sifrol, Azilect and Requip can perform to 2021, seeing potential revenues. We cover revenues for dopaminergic agents, dopamine agonists, COMT inhibitors, MAO inhibitors and other drugs for Parkinson's disease.
We discuss Boehringer Ingelheim, Novartis, GSK, Teva and many other companies. Receive industry and market information you need.
The Parkinson's treatment market has potential to expand. In 2011 there are more than 300 late-stage trials of Parkinson's drugs in progress. Find R&D trends.
Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 114 tables and charts and two research interviews (see the table of contents).
Advantages of Parkinson's Disease: World Drug Market 2011-2021 for your work
Our report gives you the following advantages in particular:
-- Find revenue predictions to 2021 for the world Parkinson's disease drug market and submarkets, seeing revenue growth
-- Discover revenue forecasts to 2021 for leading products, assessing market potentials
-- Assess leading companies, discovering their activities and prospects
-- See revenue forecasts to 2021 for leading national markets - US, Japan, UK,Germany, France, Spain, Italy, China and India
-- Review R&D for treating Parkinson's disease, seeing pipeline trends
-- Investigate competition and opportunities influencing the industry and market
-- See what will stimulate and restrain the industry and market from 2011
-- View opinion from our survey, receiving detailed interview transcripts.
There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions on Parkinson's disease, helping you to stay ahead.
Gain industry and market analysis for Parkinson's disease treatment now
Our report is for everybody needing industry and market analysis for Parkinson's disease treatments. Find trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Parkinson's Disease: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. Parkinson's Disease in 2011: A Scientific and Clinical Overview
2.1 Parkinson's is Characterised by Dopamine Depletion
2.2 Motor Symptoms of Parkinson's Disease
2.2.1 Tremor
2.2.2 Rigidity
2.2.3 Bradykinesia
2.2.4 Postural Instability
2.2.5 Other Motor Symptoms
2.3 Cognitive, Behavioural and Other Symptoms
2.3.1 Cognitive Deficits
2.3.2 Behavioural and Mood Difficulties
2.3.3 Other Symptoms
2.4 Subtypes and Possible Origin of the Disease
2.5 Timeline of Parkinson's Disease Treatment
3. The Global Market for Parkinson's Disease Drugs 2011-2021
3.1 The Parkinson's Disease Market: Overview 2011-2021
3.2 The Parkinson's Disease Market: Breakdown 2011-2021
3.3 Dopaminergic Agents: Still Key to the Market
3.3.1 Dopaminergic Agents: Market Forecast 2011-2021
3.4 Dopamine Agonists: The Foremost Commercial Class of Parkinson's Drugs
3.4.1 Dopamine Agonists: Market Forecast 2011-2021
3.5 COMT Inhibitors: The Best-Selling Class in the Parkinson's Drug Market
3.5.1 COMT Inhibitors: Market Forecast 2011-2021
3.6 MAO Inhibitors: The Fastest-Growing Market Sector
3.6.1 MAO Inhibitors: Market Forecast 2011-2021
3.7 Other Classes of Parkinson's Disease Treatment
3.7.1 Other Classes of Parkinson's Disease Treatment: Market Forecast 2011-2021
4. Leading Products in the Parkinson's Disease Treatment Market
4.1 Four Drugs Lead the Market
4.2 Stalevo and Comtess (Orion/Novartis)
4.2.1 Stalevo and Comtess: Sales Forecast 2011-2021
4.3 Sifrol (Boehringer Ingelheim)
4.3.1 Sifrol: Sales Forecast 2011-2021
4.4 Azilect (Teva Pharmaceuticals)
4.4.1 Azilect: Sales Forecast 2011-2021
4.5 Requip (GlaxoSmithKline)
4.5.1 Requip: Sales Forecast 2011-2021
4.6 Other Products
4.6.1 Other Products: Market Forecast 2011-2021
5. Leading National Markets for Parkinson's Treatments 2011-2021
5.1 The US is the Largest Market
5.2 The US: Market Forecast 2011-2021
5.3 The EU5: Market Forecasts 2011-2021
5.4 Japan: Market Forecast 2011-2021
5.5 China: Market Forecast 2011-2021
5.6 India: Market Forecast 2011-2021
5.7 Rest of the World: Market Forecast 2011-2021
6. Parkinson's Disease Treatments: R&D Pipeline Analysis 2011
6.1 There are More than 300 Late-Stage Trials of Parkinson's Drugs in Progress in 2011
6.2 KW-6002 (Kyowa Hakko Kirin) and Other Adenosine Receptor Antagonists
6.3 Safinamide (Merck Serono): Both Dopaminergic and Non-dopaminergic Effects?
6.4 Fipamezole (Santhera Pharmaceuticals)
6.5 Coenzyme Q10 (National Institute of Neurological Disorders and Stroke [NINDS], and Others)
6.6 Potential Gene Therapies
6.7 CERE-120 (Ceregene): Lead Gene-Therapy Product
6.8 Neurologix: Another Gene Therapy Candidate
6.9 Possible Disease-Modifying Treatments
7. Top Companies in the Parkinson's Disease Treatments Market 2011
7.1 Boehringer Ingelheim
7.2 Novartis
7.3 Orion
7.4 Teva Pharmaceutical Industries
7.5 GlaxoSmithKline
7.6 Impax Laboratories
7.7 Kyowa Hakko Kirin
7.8 Merck Serono
7.9 Newron
7.10 Ceregene
7.11 Neurologix
7.12 Santhera
7.13 Biotie
7.14 Merck & Co
7.15 Xenoport
8. Parkinson's Treatment Market: Qualitative Analysis
8.1 Strengths: Parkinson's Disease is a Widely Prevalent and Treatable Disease
8.2 Weaknesses: Products on the Market Have Limitations and Can Be Superseded
8.3 Opportunities: Neurodegenerative Disorder Treatments Are a Fertile R&D Area
8.4 Threats: New Parkinson's Treatments May Be Subject to Political, Commercial and Social Pressures
9. Research Interviews from Our Survey
9.1 Interview with Dr Kieran Breen
9.1.1 On Current Treatment Options for Parkinson's Disease
9.1.2 On Prospective New Drugs
9.1.3 On Cell Death and Neuroprotection
9.1.4 On Braak's Hypothesis and Parkinson's Disease Progression
9.1.5 On Disease Heterogeneity and Potential Biomarkers
9.1.6 On Growth Factors, Gene Therapies and Stem Cells
9.1.7 On Brain-Banking and Animal Models
9.2 Interview with Professor Rammohan Rao
9.2.1 On the Role of the Endoplasmic Reticulum in Cell Death
9.2.2 On Therapeutic Applications of That Research
9.2.3 On Challenges in the Parkinson's Disease Field in 2011
10. Conclusions from Our Study
10.1 Parkinson's Disease Treatment Market to 2021
10.2 A Promising But Unproven Pipeline
10.3 Other Factors Will Benefit the Parkinson's Disease Treatment Market
List of Tables
Table 2.1 Timeline of Parkinson's Disease
Table 3.1 Parkinson's Disease Drug Market: Total World Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.2 Parkinson's Disease Drug Market: Total World Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 3.3 Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2010
Table 3.4 Parkinson's Disease Drug Market: Breakdown by Mechanism of Action, Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.5 Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2015
Table 3.6 Parkinson's Disease Drug Market, Breakdown by Mechanism of Action: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 3.7 Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2021
Table 3.8 Dopaminergic Agents: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.9 Dopaminergic Agents: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 3.10 Dopamine Agonists: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.11 Dopamine Agonists: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 3.12 COMT Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.13 COMT Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 3.14 MAO Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.15 MAO Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 3.16 Other Parkinson's Treatments: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.17 Other Parkinson's Treatments: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 4.1 Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2010
Table 4.2 Leading Parkinson's Disease Drugs: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.3 Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2015
Table 4.4 Leading Parkinson's Disease Drugs: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.5 Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2021
Table 4.6 US Patent Expiry Dates for Leading Parkinson's Disease Drugs, 2008-2017
Table 4.7 Stalevo & Comtess Revenues: Breakdown by Company, 2010
Table 4.8 Stalevo & Comtess: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.9 Stalevo & Comtess: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 4.10 Sifrol: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.11 Sifrol: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 4.12 Azilect: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.13 Azilect: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 4.14 Requip: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.15 Requip: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 4.16 Other Products Approved for Parkinson's Disease Treatment, 2011
Table 4.17 Other Products: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.18 Other Products: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.1 Leading National Markets: Revenues ($m), Market Shares (%), 2010
Table 5.2 Leading National Markets: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.3 Leading National Markets: Revenues ($m), Market Shares (%), 2015
Table 5.4 Leading National Markets: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.5 Leading National Markets: Revenues ($m), Market Shares (%), 2021
Table 5.6 US Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.7 US Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.8 EU5 Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.9 EU5 Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.10 EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2010
Table 5.11 EU5 Market: National Breakdown, Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.12 EU5 Market: National Breakdown, Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.13 EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2021
Table 5.14 Japanese Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.15 Japanese Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.16 Chinese Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.17 Chinese Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.18 Indian Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.19 Indian Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.20 Rest of the World Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.21 Rest of the World Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 6.1 Some Key Products in the Late-Stage Pipeline, 2011
Table 8.1 Strengths, Weaknesses, Opportunities and Threats in the Parkinson's Drug Market, 2011
List of Figures
Figure 2.1 The Five Stages of Parkinson's Disease
Figure 3.1 Parkinson's Disease Drug Market: Total World Revenues ($m), 2010-2015
Figure 3.2 Parkinson's Disease Drug Market: Total World Revenues ($m), 2016-2021
Figure 3.3 Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2010
Figure 3.4 Parkinson's Disease Drug Market: Breakdown by Mechanism of Action, Revenues ($m), 2010-2015
Figure 3.5 Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2015
Figure 3.6 Parkinson's Disease Drug Market: Breakdown by Mechanism of Action, Revenues ($m), 2016-2021
Figure 3.7 Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2021
Figure 3.8 Dopaminergic Agents: Revenues ($m), 2010-2015
Figure 3.9 Dopaminergic Agents: Revenues ($m), 2016-2021
Figure 3.10 Dopamine Agonists: Revenues ($m), 2010-2015
Figure 3.11 Dopamine Agonists: Revenues ($m), 2016-2021
Figure 3.12 COMT Inhibitors: Revenues ($m), 2010-2015
Figure 3.13 COMT Inhibitors: Revenues ($m), 2016-2021
Figure 3.14 MAO Inhibitors: Revenues ($m), 2010-2015
Figure 3.15 MAO Inhibitors: Revenues ($m), 2016-2021
Figure 3.16 Other Parkinson's Treatments: Revenues ($m), 2010-2015
Figure 3.17 Other Parkinson's Treatments: Revenues ($m), 2016-2021
Figure 4.1 Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2010
Figure 4.2 Leading Parkinson's Disease Drugs: Revenues ($m), 2010-2015
Figure 4.3 Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2015
Figure 4.4 Leading Parkinson's Disease Drugs: Revenues ($m), 2016-2021
Figure 4.5 Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2021
Figure 4.6 Stalevo & Comtess Revenues: Breakdown by Company, 2010
Figure 4.7 Stalevo & Comtess: Revenues ($m), 2010-2015
Figure 4.8 Stalevo & Comtess: Revenues ($m), 2016-2021
Figure 4.9 Sifrol: Revenues ($m), 2010-2015
Figure 4.10 Sifrol: Revenues ($m), 2016-2021
Figure 4.11 Azilect: Revenues ($m), 2010-2015
Figure 4.12 Azilect: Revenues ($m), 2016-2021
Figure 4.13 Requip: Revenues ($m), 2010-2015
Figure 4.14 Requip: Revenues ($m), 2016-2021
Figure 4.15 Other Products: Revenues ($m), 2010-2015
Figure 4.16 Other Products: Revenues ($m), 2016-2021
Figure 5.1 Leading National Markets: Revenues ($m), Market Shares (%), 2010
Figure 5.2 Leading National Markets: Revenues ($m), 2010-2015
Figure 5.3 Leading National Markets: Revenues ($m), Market Shares (%), 2015
Figure 5.4 Leading National Markets: Revenues ($m), 2016-2021
Figure 5.5 Leading National Markets: Revenues ($m), Market Shares (%), 2021
Figure 5.6 US Market: Revenues ($m), 2010-2015
Figure 5.7 US Market: Revenues ($m), 2016-2021
Figure 5.8 EU5 Market: Revenues ($m), 2010-2015
Figure 5.9 EU5 Market: Revenues ($m), 2016-2021
Figure 5.10 EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2010
Figure 5.11 EU5 Market: National Breakdown, Revenues ($m), 2010-2015
Figure 5.12 EU5 Market: National Breakdown, Revenues ($m), 2016-2021
Figure 5.13 EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2021
Figure 5.14 Japanese Market: Revenues ($m), 2010-2015
Figure 5.15 Japanese Market: Revenues ($m), 2016-2021
Figure 5.16 Chinese Market: Revenues ($m), 2010-2015
Figure 5.17 Chinese Market: Revenues ($m), 2016-2021
Figure 5.18 Indian Market: Revenues ($m), 2010-2015
Figure 5.19 Indian Market: Revenues ($m), 2016-2021
Figure 5.20 Rest of the World Market: Revenues ($m), 2010-2015
Figure 5.21 Rest of the World Market: Revenues ($m), 2016-2021
Companies Listed
Abbott Laboratories
Acadia Pharmaceuticals
Amgen
Axxonis Pharma
Biotie
BioSante Pharmaceuticals
Biovail
Boehringer Ingelheim
Brainstorm Cell Therapeutics
Buck Institute for Research on Aging
Ceregene
Chelsea Therapeutics
Ciba-Geigy
Cipla
Columbia University
Dainippon Sumitomo
Dresden University of Technology
Eisai
EMEA/EMA
Endo Pharmaceuticals
Erba
Farmitalia Carlo
FDA [US]
Impax Laboratories
GlaxoSmithKline
Ipsen
Juvantia Pharma
Kaneka Nutrients
Kyowa Hakko Kirin
Lundbeck
Maypro Industries
Merck & Co.
Merck KGaA
Merck Serono
Mitsubishi Gas Chemical
Mylan
National Institute of Neurological Disorders and Stroke [NINDS]
Neupro
Neurologix
Newron Pharmaceuticals
NINDS
Novartis
Orion
Oxford BioMedica
Pacific Rainbow International
Parkinson's UK
Parr
Pfizer
Pharmacia
Roche
Roxane
Sandoz
Santhera
Schering Plough
Servier
ShenZhou Biology & Technology
Solvay Pharmaceuticals
Sun Pharmaceuticals
Synergen Corporation
Synosia Therapeutics
Teva Pharmaceutical Industries
UCB
University of Bristol Institute of Clinical Neuroscience
University of Kentucky
University of Nebraska
University of Rochester
Valeant
Watson Pharmaceuticals
Weill Medical College, Cornell University
Wockhardt
Xenoport
Xiamen Kingdomway Group
Zhejiang Medicine Company
To order this report:
Drug and Medication Industry: Parkinson%s Disease: World Drug Market 2011-2021
Drug and Medication Business News
Check our Industry Analysis and Insights
Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article